Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Pebean Pharma ApS
APS
Active
CVR 44427737
Klosterbakken 22
Activities of holding companies · NACE 6421
Est. 2023
— employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
DKK 1,6M
EBITDA margin
97.0%
Equity ratio
78.5%
Financial strength
Net profit 2024
DKK 1,2M
EBITDA — year on year
DKK millions
3M
2M
1M
1M
0M
2M
2024
Key figures
Annual report 2024
Revenue
DKK 1,6M
—
EBITDA
DKK 1,5M
—
Net profit
DKK 1,2M
—
Total assets
DKK 1,6M
—
Equity
DKK 1,2M
—
Employees
—
—
Company information
Legal name
Pebean Pharma ApS
CVR number
44427737
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
13. november 2023
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør eller af den samlede direktion.
Company purpose
Selskabets formål er at eje kapitalandele, farmaceutiske licensaftaler og patenter samt hermed beslægtet virksomhed.
Contact
Address
Klosterbakken 22
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Activities of holding companies
Companies in Furesø
All Denmark companies
Revenue
DKK millions
0M
1M
1M
2M
2M
2M
2024
EBITDA
DKK millions
0M
1M
1M
2M
2M
2M
2024
Income statement
DKK thousands
Item
2024
Revenue
1.586
Staff expenses
-0
EBITDA
1.539
Depreciation & amort.
-12
EBIT
1.527
Net financials
-6
Profit before tax
1.521
Tax
336
Net profit
1.185
Balance sheet
DKK thousands
Item
2024
Total assets
1.561
Equity
1.225
Long-term debt
0
Short-term debt
336
Total debt
336
Financial ratios
5-year trend
EBITDA margin
97.0%
This company
15.8%
Market median
+514% vs market
2024
2024
Equity ratio
78.5%
This company
38.2%
Market median
+105% vs market
2024
2024
Return on equity
96.7%
This company
18.4%
Market median
+426% vs market
2024
2024
Net profit margin
74.7%
This company
8.1%
Market median
+822% vs market
2024
2024
Asset turnover
1.02×
This company
1.12×
Market median
+9% vs market
2024
2024
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via CVR / Virk · Period 2023-11-13 – 2024-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (3)
PG
Peter Gudmund Nielsen
Chief Executive Officer
Chief Executive Officer
2023
BH
Bent Højgaard
Management
Management
2023
AV
Ann Vivian Fullerton
Management
Management
2023
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Helida Holding ApS
Company
33.33–49.99%
33.33–49.99%
2023
Alvina Holding ApS
Company
25–33.32%
25–33.32%
2023
Cacaam Holding ApS
Company
25–33.32%
25–33.32%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Alvina Holding ApS
Pebean Pharma ApS
(this company)
ROS Therapeutics Holding ApS
ROS Therapeutics ApS
Board network connections
Board members of Pebean Pharma ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Peter Gudmund Nielsen
Chief Executive Officer
0 companies
Bent Højgaard
Management
0 companies
Ann Vivian Fullerton
Management
0 companies